Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
IMMP1LP2, or inner mitochondrial membrane peptidase subunit 1 pseudogene 2, is a noncoding genomic sequence classified as a pseudogene. Pseudogenes are defective copies of functional genes that have accumulated mutations (such as frameshifts, stop codons, or lack of necessary regulatory elements), losing their protein-coding capacity and, typically, their original function. While some pseudogenes have been implicated in gene regulation, particularly as miRNA decoys or through other noncoding RNA-based mechanisms, there is currently no evidence that IMMP1LP2 itself has a demonstrable impact on human physiology, pathology, or drug response. As such, it is not categorized as a therapeutic target or biomarker in biomedical research or clinical use.
Not applicable
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Inner mitochondrial membrane peptidase subunit 1 pseudogene 2 (IMMP1LP2).